Osteoporosis: Why Your Bones Are Silently Thinning and What Stops It

Osteoporosis is a skeletal disease characterized by reduced bone mass and microarchitectural deterioration of bone tissue, leading to increased bone fragility and susceptibility to fracture. It is, by definition, a silent disease: bones thin progressively over years without pain, warning signs, or detectable symptoms — until a fracture occurs. An estimated 10 million Americans have osteoporosis, and another 44 million have osteopenia (below-normal bone density that precedes osteoporosis). Osteoporotic fractures are not minor injuries; hip fractures in older adults carry a 20 to 30 percent mortality rate within one year, and 40 percent of survivors never return to pre-fracture functional status. The goal of osteoporosis management is fracture prevention, and the tools to achieve it are well established.

How Bone Remodeling Works and Where It Goes Wrong

Bone is a metabolically active tissue undergoing continuous remodeling — osteoclasts resorb old bone, and osteoblasts form new bone. In youth, formation exceeds resorption, and bone density peaks at approximately age 25 to 30. After peak bone mass is achieved, a gradual net loss begins. In women, the accelerated estrogen withdrawal of menopause dramatically shifts the remodeling balance toward resorption: bone density can fall by three to five percent per year in the first five years after menopause, a pace that may add ten to fifteen percent cumulative bone loss before stabilizing. In men, testosterone decline with aging produces a slower but real loss. The result is a skeleton that is progressively less mineralized and more porous — particularly the trabecular (spongy) bone of the spine, hips, and wrist, which are the primary sites of osteoporotic fracture.

Understanding Bone Density Measurements

DEXA Scan

Dual-energy X-ray absorptiometry (DEXA) is the gold-standard, low-radiation imaging test for measuring bone mineral density (BMD). It is painless, takes approximately 10 to 15 minutes, and delivers radiation exposure roughly equivalent to a few hours of background radiation. DEXA is typically performed at the lumbar spine (L1–L4) and proximal femur (total hip and femoral neck). Results are reported as T-scores and Z-scores.

T-Score

The T-score compares a patient's BMD to that of a healthy 30-year-old of the same sex at peak bone mass. World Health Organization thresholds:

• T-score ≥ -1.0: Normal bone density
• T-score between -1.0 and -2.5: Osteopenia (low bone mass)
• T-score ≤ -2.5: Osteoporosis
• T-score ≤ -2.5 plus one or more fragility fractures: Severe (established) osteoporosis

Each one standard deviation decrease in T-score roughly doubles the risk of fracture. A T-score of -2.5 at the hip is associated with approximately a 25 percent lifetime risk of hip fracture in a 50-year-old woman.

Z-Score

The Z-score compares BMD to age-matched peers. A Z-score below -2.0 suggests bone loss exceeding what age alone would explain and prompts investigation for secondary causes of osteoporosis.

Who Should Be Screened

The US Preventive Services Task Force (USPSTF) recommends DEXA screening for:

• All women 65 years and older
• Postmenopausal women under 65 whose 10-year fracture risk (by FRAX) equals or exceeds that of a 65-year-old white woman with no additional risk factors (approximately 9.3% 10-year major osteoporotic fracture risk)

Most clinical societies additionally recommend screening men at 70 and older, and earlier evaluation for both men and women with significant risk factors. The USPSTF currently concludes that evidence is insufficient to recommend for or against screening men, though many guidelines support it at 70 given the high post-fracture mortality in older men.

Risk Factors for Osteoporosis

Major non-modifiable risk factors include female sex, advanced age, white or Asian ethnicity, family history of osteoporosis, and small frame/low body weight (BMI below 20 is independently associated with low bone density). Modifiable risk factors include: estrogen deficiency (surgical or natural menopause before age 45 substantially increases lifetime fracture risk); chronic glucocorticoid use (prednisone ≥5 mg/day for more than three months is a major cause of secondary osteoporosis); smoking (directly inhibits osteoblasts and accelerates bone loss); heavy alcohol use (more than two drinks daily); prolonged immobility; and dietary deficiencies in calcium and vitamin D.

Secondary Causes of Osteoporosis

A significant proportion of osteoporosis cases — particularly in younger patients, men, or those with unexpectedly low Z-scores — have identifiable secondary causes: hyperparathyroidism (primary or secondary), hyperthyroidism, celiac disease and malabsorption, inflammatory bowel disease, rheumatoid arthritis, anorexia nervosa, medications (glucocorticoids, aromatase inhibitors, GnRH agonists, antiepileptics, proton pump inhibitors with prolonged use, SSRI), chronic kidney disease, and multiple myeloma. A targeted secondary workup including serum calcium, 25-hydroxyvitamin D, PTH, thyroid function, and complete metabolic panel is appropriate in patients with unexplained low bone density.

FRAX Score: Beyond Bone Density Alone

The FRAX algorithm (from the World Health Organization) calculates an individual's 10-year probability of major osteoporotic fracture (hip, clinical spine, forearm, or proximal humerus) using twelve clinical variables, with or without femoral neck BMD. FRAX is important because bone density alone does not fully capture fracture risk — a patient with multiple clinical risk factors but only modestly reduced bone density may have higher absolute fracture risk than a patient with low T-score but no other risk factors. Current National Osteoporosis Foundation guidelines recommend initiating treatment when the 10-year hip fracture probability exceeds 3 percent or the 10-year major osteoporotic fracture probability exceeds 20 percent — thresholds at which the cost-effectiveness of treatment is well established.

Calcium and Vitamin D

Calcium and vitamin D are foundational — necessary conditions for bone health rather than treatments per se. Recommended intakes: 1000 mg/day of elemental calcium for adults under 50, 1200 mg/day for women over 50 and adults over 70 (from dietary sources preferentially); 600 IU/day of vitamin D for adults under 70, 800 IU/day for those over 70. Achieving vitamin D sufficiency (25-hydroxyvitamin D level above 30 ng/mL) optimizes calcium absorption. The evidence base for calcium and vitamin D alone reducing fracture risk in non-institutionalized adults is modest; they are necessary background support for pharmacological treatment rather than primary therapy for established osteoporosis.

Pharmacological Treatment

Bisphosphonates: First-Line Therapy

Bisphosphonates — alendronate (Fosamax), risedronate (Actonel), zoledronic acid (Reclast), ibandronate (Boniva) — are the most widely used and best-studied osteoporosis medications. They bind to bone mineral and inhibit osteoclast-mediated bone resorption, reducing both vertebral and non-vertebral fracture risk. Alendronate reduces vertebral fracture risk by approximately 50 percent and hip fracture risk by 40 to 50 percent in patients with prior vertebral fracture. Zoledronic acid, given as a yearly intravenous infusion, is a good option for patients with GI intolerance to oral agents or adherence challenges. A drug holiday (stopping bisphosphonates after three to five years) is appropriate for low-to-moderate risk patients, as the benefits persist due to the long skeletal residence time of bisphosphonates. For high-risk patients (multiple fractures, very low T-scores), longer treatment or sequential therapy is indicated.

Denosumab (Prolia)

Denosumab is a monoclonal antibody against RANKL, a cytokine essential for osteoclast differentiation and survival. Given as a subcutaneous injection every six months, it reduces vertebral fracture risk by 68 percent and hip fracture risk by 40 percent. Denosumab is an excellent option for patients with renal impairment (unlike bisphosphonates, which are contraindicated in severe CKD) and for patients with inadequate response to bisphosphonates. However, a critical safety consideration: discontinuing denosumab without transitioning to another antiresorptive agent causes a rebound increase in bone resorption and significantly elevated fracture risk for 12 to 18 months. Denosumab should not be stopped abruptly without a plan to bridge with a bisphosphonate.

Anabolic Agents: Building Bone

Antiresorptive agents prevent further bone loss; anabolic agents actually build new bone — a meaningful distinction for patients with severe disease. Teriparatide (Forteo) and abaloparatide (Tymlos) are PTH receptor agonists that stimulate osteoblasts, increasing bone formation. They are given as daily subcutaneous injections and increase spinal BMD by 8 to 13 percent over 18 to 24 months, with 65 to 68 percent reduction in vertebral fractures. They are indicated for high-risk patients with multiple fractures or severely low T-scores. Treatment duration is limited to 24 months (lifetime) due to osteosarcoma risk observed in rat studies at supratherapeutic doses (though this has not been observed in clinical use); treatment must be followed by an antiresorptive agent to preserve gains. Romosozumab (Evenity) is a more recent anabolic agent — a monoclonal antibody against sclerostin — that both stimulates bone formation and inhibits resorption, given monthly by injection for 12 months. It produces the largest BMD gains of any currently available agent. A black box warning for cardiovascular events limits its use in patients with recent heart attack or stroke.

Fall Prevention

Treating osteoporosis without addressing fall risk is incomplete care. Approximately 90 percent of hip fractures result from falls. Fall prevention strategies with evidence include: balance and resistance exercise programs (particularly Tai Chi, which reduces fall rates by 23 to 45 percent in trials); vision correction (annual eye exams, cataract treatment); medication review and deprescribing of high-risk agents (sedatives, opioids, anticholinergics, blood pressure medications causing orthostatic hypotension); home hazard modification (removing loose rugs, improving lighting, installing grab bars in bathrooms); and footwear assessment. Multifactorial fall prevention programs in primary care reduce falls by approximately 20 to 30 percent in high-risk older adults.

When to See a Doctor

If you are a woman over 65, postmenopausal under 65 with risk factors, a man over 70, or anyone who has experienced a fragility fracture (a fracture from a fall from standing height or less), a bone density evaluation and fracture risk assessment are warranted. Treatment that reduces fracture risk by 40 to 65 percent is available and effective — but only if initiated. JourneyDoctors connects you with trained specialists from $19. Start a consultation today — no waiting room, no referral needed.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment.

Frequently Asked Questions

What is a fragility fracture?

A fragility fracture is a fracture that results from low-energy trauma — typically a fall from standing height or less — that would not have broken a normal, healthy bone. Common sites are the vertebrae (spinal compression fractures, which can cause height loss and back pain), hip, wrist, and humerus. A fragility fracture at any site is diagnostic of severe osteoporosis and mandates initiation of pharmacological treatment, regardless of DEXA results. It is also a strong predictor of subsequent fracture — the fracture cascade — making treatment urgency high.

Do bisphosphonates cause unusual bone fractures?

Atypical femoral fractures (AFFs) — a rare type of stress fracture in the femoral shaft — are associated with long-term bisphosphonate use, particularly beyond five to seven years. The incidence is very low: approximately 3 to 50 per 100,000 patient-years. Compared to the fractures prevented by bisphosphonate treatment, the risk-benefit balance remains strongly in favor of treatment, particularly in the first five years. Patients on bisphosphonates should be monitored for thigh or groin pain (a prodromal symptom of AFF) and reassessed for drug holiday eligibility after three to five years of use.

Can osteoporosis be reversed?

Pharmacological treatment cannot fully reverse osteoporosis, but it can meaningfully increase bone density — particularly anabolic agents — and dramatically reduce fracture risk. Anabolic agents (teriparatide, romosozumab) can increase vertebral BMD by 8 to 15 percent over treatment courses, which is clinically significant. More practically, reducing fracture risk by 40 to 70 percent with available treatments is the relevant clinical goal, even in the absence of T-score normalization.

Is osteoporosis only a women's disease?

No. Men account for approximately 20 percent of osteoporotic fractures, and hip fractures in men carry higher mortality than in women — approximately 37 percent within one year. Men are significantly underdiagnosed and undertreated for osteoporosis because of lower screening rates and the perception that it is a female disease. Risk factors in men include hypogonadism, glucocorticoid use, alcohol use, smoking, and secondary causes. Men with fragility fractures or significant risk factors should be screened and treated as aggressively as women.

How long do I need to take osteoporosis medication?

Treatment duration depends on the agent, the patient's fracture risk, and monitoring findings. For bisphosphonates, a treatment reassessment and potential drug holiday after three to five years is appropriate for low-to-moderate risk patients, with continued treatment for high-risk patients. Denosumab is typically continued indefinitely or transitioned to a bisphosphonate, as abrupt discontinuation causes rebound bone loss. Anabolic agents have a maximum duration of 24 months; they are followed by an antiresorptive agent to maintain gains. No treatment is forever-fixed; it is adjusted based on evolving risk, response, and tolerance.